DexCom, Inc.

DXCM

Market Cap$34.89B

Volume3.05M

Revenue$4.15B

Gross Profits$2.47B

Employees10200

EquityMedical DevicesHealthcareUSDwww.dexcom.com/global

About

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes...

AI Summary

Model	Near-Term (0-3 mo.)	Mid-Term (3-12 mo.)	Long-Term (1-5 yr.)
Deepseek	Hold	Buy	Strong Buy
OpenAI	Buy	Hold	Buy
Gemini	Buy	Hold	Hold
Grok	Buy	Hold	Buy

Detailed Analysis

Deepseek

Holdnear term

Current price is above the fifty-day average, indicating potential short-term consolidation.

Valuation:Forward P/E suggests high growth expectations.

Technical:Price above short-term average but may face resistance.

Sentiment:Market sentiment is positive but cautious due to high beta.

News:No significant news expected to drive immediate price action.

Buymid term

Strong sector performance and growth prospects support a bullish outlook.

Valuation:Trailing PEG ratio indicates reasonable growth relative to earnings.

Technical:Sustained price above 200-day average supports upward trend.

Sentiment:Positive sector sentiment and innovation in healthcare could boost interest.

News:Potential for positive developments in product pipeline.

Strong Buylong term

Long-term growth in healthcare and continuous innovation likely to drive performance.

Valuation:High forward P/E reflects long-term growth potential.

Technical:Long-term trend is upward, supported by sector growth.

Sentiment:Strong investor confidence in healthcare innovation.

News:Expected to lead in diabetes care technology advancements.

Gemini

Buynear term

Positive momentum above 50 and 200-day averages suggests continued short-term gains.

Valuation:Forward P/E is high, suggesting overvaluation.

Technical:Price above 50 and 200-day averages indicates bullish trend.

Sentiment:Market sentiment is likely positive given recent price action.

News:Assuming no negative news, trend should continue.

Holdmid term

High valuation and beta of 1.461 introduce volatility and uncertainty.

Valuation:High forward P/E and PEG ratio suggest limited upside.

Technical:Needs to consolidate gains to maintain upward trajectory.

Sentiment:Market sentiment could shift based on earnings reports.

News:Monitor for new product launches and market penetration.

Holdlong term

Growth potential is tempered by valuation concerns and sector competition.

Valuation:Long-term growth needs to justify current valuation.

Technical:Long-term trend needs to remain positive to support investment.

Sentiment:Long-term market sentiment depends on industry growth.

News:Monitor for innovation and competitive advantages.

Openai

Buynear term

Current technicals suggest a positive short-term outlook with upward price momentum.

Valuation:High forward PE, suggesting premium pricing.

Technical:Price above 50 and 200-day averages indicating upward trend.

Sentiment:Generally positive market sentiment towards healthcare sector.

News:No significant news impacting immediate stock performance.

Holdmid term

While the stock shows growth potential, high valuation may cap significant gains.

Valuation:Elevated valuation metrics could limit mid-term growth.

Technical:Consistent performance but watch for potential resistance levels.

Sentiment:Stable sentiment with cautious optimism in healthcare investments.

News:Monitor for any strategic company developments or sector shifts.

Buylong term

Long-term growth potential in healthcare technology remains strong.

Valuation:Long-term growth could justify current high valuation levels.

Technical:Historical performance suggests solid long-term upward trajectory.

Sentiment:Positive long-term outlook on healthcare innovation.

News:Potential for significant advancements or partnerships in healthcare tech.

Grok

Buynear term

Current price above 50-day average signals short-term strength. Momentum may continue with positive technicals.

Valuation:High forward P/E at 42.1 suggests overvaluation.

Technical:Price above 50-day average indicates bullish momentum.

Sentiment:Market sentiment appears neutral without major shifts.

News:No significant recent news impacting near-term outlook.

Holdmid term

High valuation and beta suggest caution amid volatility. Growth potential balanced by market risks.

Valuation:Trailing PEG ratio of 1.31 indicates fair growth pricing.

Technical:Price above 200-day average supports moderate bullishness.

Sentiment:Healthcare sector sentiment remains cautiously optimistic.

News:Limited news; monitor for product or regulatory updates.

Buylong term

Strong healthcare sector growth supports long-term upside. DXCM likely to benefit from innovation trends.

Valuation:High P/E acceptable for long-term growth prospects.

Technical:Long-term trends less relevant; focus on fundamentals.

Sentiment:Positive long-term outlook for healthcare technology.

News:Expect positive developments in diabetes management tech.